End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 CNY | -0.32% | +1.61% | -5.97% |
04-25 | Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan | MT |
Chart calendar Harbin Pharmaceutical Group Co., Ltd.
Upcoming events on Harbin Pharmaceutical Group Co., Ltd.
Past events on Harbin Pharmaceutical Group Co., Ltd.
2024-04-25 | Q1 2024 Earnings Release |
2024-04-10 | Q4 2023 Earnings Release |
2023-12-27 02:00 | Extraordinary Shareholders Meeting |
2023-10-26 | Q3 2023 Earnings Release |
2023-08-24 | Q2 2023 Earnings Release |
2023-06-15 02:00 | Annual General Meeting |
2023-04-27 | Q1 2023 Earnings Release |
2023-04-10 | Q4 2022 Earnings Release |
2022-12-22 | Extraordinary Shareholders Meeting |
2022-10-26 | Q3 2022 Earnings Release |
2022-08-25 | Interim 2022 Earnings Release |
2022-06-27 02:00 | Annual General Meeting |
2022-04-27 | Q1 2022 Earnings Release |
2022-04-08 | FY 2021 Earnings Release |
2022-03-22 02:00 | Extraordinary Shareholders Meeting |
2021-12-20 01:00 | Extraordinary Shareholders Meeting |
2021-10-25 | Q3 2021 Earnings Release |
2021-08-15 | Interim 2021 Earnings Release |
2021-06-25 02:00 | Annual General Meeting |
2021-04-27 | Q1 2021 Earnings Release |
Past dividends on Harbin Pharmaceutical Group Co., Ltd.
2018-05-03 | Annual 0.5 CNY |
2017-04-12 | Annual 0.5 CNY |
2015-11-12 | Interim Payment 1 CNY |
2014-08-25 | Annual 0.066 CNY |
Annual results
Fiscal Period | December | 2020 |
---|---|---|
Net sales | Released Forecast Spread | 0,00 |
EBITDA | Released Forecast Spread | 0,00 |
EBIT | Released Forecast Spread | 0,00 |
Earnings before Tax (EBT) | Released Forecast Spread | 0,00 |
Net income Million CNY | Released Forecast Spread | -1 078 |
EPS CNY | Released Forecast Spread | -0,43 |
Announcement Date | 02/04/21 |
Past sector events for Harbin Pharmaceutical Group Co., Ltd.
- Stock Market
- Equities
- 600664 Stock
- Calendar Harbin Pharmaceutical Group Co., Ltd.